-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, Nf0Xlf7v0Mo6gBzDsNcJv8n8/Ak+MPgysJfOjC1rAvRc9aUEM8WwzPBAkSen0/2P 6QoOKyvjvV1iBVbTckgNMQ== 0001088020-03-000016.txt : 20030214 0001088020-03-000016.hdr.sgml : 20030214 20030214140751 ACCESSION NUMBER: 0001088020-03-000016 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20030128 ITEM INFORMATION: Other events FILED AS OF DATE: 20030214 FILER: COMPANY DATA: COMPANY CONFORMED NAME: DERMA SCIENCES INC CENTRAL INDEX KEY: 0000892160 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 232328753 STATE OF INCORPORATION: PA FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-13070 FILM NUMBER: 03566033 BUSINESS ADDRESS: STREET 1: 214 CARNEGIE CENTER, SUITE 100 CITY: PRINCETON STATE: NJ ZIP: 08540 BUSINESS PHONE: 6095144744 MAIL ADDRESS: STREET 1: 214 CARNEGIE CENTER, SUITE 100 CITY: PRINCETON STATE: NJ ZIP: 08540 8-K 1 form8k_012803.htm JANUARY 28, 2003 Derma Sciences, Inc. Form 8-K dated January 28, 2003


SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549




FORM 8-K


CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d)
OF THE SECURITIES EXCHANGE ACT OF 1934




Date of Report (Date of earliest event reported):  January 28, 2003



Derma Sciences, Inc.
(Exact name of registrant as specified in its charter)


Pennsylvania 1-31070 23-2328753
(State or other jurisdiction (Commission (IRS employer
of incorporation) File Number) identification number)




214 Carnegie Center, Suite 100
Princeton, NJ 08540
(609) 514-4744
(Address including zip code and telephone
number, of principal executive offices)


Item 5. Other Events and Regulation FD Disclosure

        On January 28, 2003 Derma Sciences, Inc. (the “Registrant”) notified Capital Source Finance LLC (“Capital”) of the Registrant’s intent to terminate its revolving credit facility with Capital established April 30, 2002. The effective date of this termination is March 1, 2003. Prior to March 1, 2003 the Registrant will satisfy from cash-on-hand its obligations to Capital consisting of principal and termination fees totaling $1,050,000, together with accrued interest. The Registrant intends to replace the Capital revolving credit facility with a credit facility incorporating terms more advantageous to it than the Capital facility.

        For further information concerning the Capital revolving credit facility please refer to the Registrant’s current report on Form 8-K filed May 22, 2002.



2

        Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

    DERMA SCIENCES, INC.
     
     
     
Date: February 12, 2003   By: /s/ John E. Yetter     
      John E. Yetter, CPA
      Vice President and Chief Financial Officer



3

 -----END PRIVACY-ENHANCED MESSAGE-----